What is Prometheus Biosciences?
Founded in 1995 and headquartered in San Diego, California, Prometheus Biosciences is dedicated to the development of innovative diagnostics, therapeutics, and pharmaceuticals targeting gastrointestinal and autoimmune diseases. The company's focus on unmet medical needs in these complex areas positions it as a key player in the life sciences industry, aiming to advance patient care through scientific innovation.
How much funding has Prometheus Biosciences raised?
Prometheus Biosciences has raised a total of $260M across 1 funding round:
Debt
$260M
Debt (2010): $260M, investors not publicly disclosed
What's next for Prometheus Biosciences?
The substantial enterprise-level funding, including the recent strategic investment, signals Prometheus Biosciences' readiness for accelerated development and market expansion. This capital infusion is expected to fuel further research and development initiatives, potentially leading to the advancement of its pipeline candidates through clinical trials and towards commercialization. The company is poised to leverage this financial backing to solidify its market presence and address critical challenges in autoimmune and GI disease treatment.
See full Prometheus Biosciences company page
